Fully Decentralised Clinical Study Exploring Remote Collection of Glycaemic and Behaviometric Data Among Participants With Type 2 Diabetes Mellitus on Different Treatment Regimens
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 156
- 试验地点
- 1
- 主要终点
- Participant invited to consent and consented via e-signature (Yes/No)
研究概览
简要总结
Earlier protocol ID was NN1250-4630, protocol ID is changed to NN1535-7774. The purpose of this study is to collect blood glucose values and activity data in patients with type 2 diabetes for approximately 12 weeks using electronic devices in a full virtual clinical setting. Virtual clinical setting means that all data are collected by use of participants' personal smartphone and study-related apps. In other words, everything will be handled without any visits to a hospital or doctor.
For collection of participants' blood glucose values participants will receive two different blood glucose monitors. One where participants cannot see the blood glucose values and one where participants can see the blood glucose values. Participants must wear them consecutively for 2 and 10 weeks, respectively. Further, participants will be asked to self-apply the monitors on their upper arm.
For collection of participants' activity data participants will receive an activity tracker, which participants will wear on the wrist throughout the study.
The study does not include any study medication and participants will continue the current antidiabetic treatment as prescribed to participants by their own physician. If any questions about the treatment and/or health condition while participating in the trial, participants should consult your own physician If participants are in doubt about what the blood glucose values mean or whether participants should react to the blood glucose values, participants need to contact the research staff or their general practitioner.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willingness to consent via the e-consent process before any study-related activities takes place (study-related activities are any procedure related to recording of data according to the protocol)
- •Male or female, age above or equal to 18 years at the time of signing informed consent
- •Diagnosed T2DM for more than 3 months prior to signing the informed consent
- •On one of the following treatments for T2DM:
- •Metformin ± other OADs
- •Basal insulin ± OADs
- •GLP-1 ± Basal insulin (loose and fixed combination) ± OADs
- •Willingness to, and capable of applying and using the study devices
- •Willingness to follow study procedures
- •Fluent in Danish both oral, reading and in writing
- •In possession of a compatible smartphone throughout the study, meaning that the smartphone fulfils the criteria to the operating system for using the devices needed for the study
排除标准
- •Previous participation in this study. Participation is defined as having given informed consent in this study
- •Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- •Participation in any other study investigating diabetes.
- •Patients who do not have a blood glucose meter at home
研究组 & 干预措施
Other oral antidiabetic drugs (OADs) ± metformin
Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician
干预措施: Oral antidiabetetic drugs (Drug)
Basal insulin ± OADs
Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician
干预措施: Basal insulin (Drug)
Glucagon-like peptide-1 (GLP-1) ± Basal insulin (loose and fixed combination) ± OADs
Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician
干预措施: Basal insulin (Drug)
Glucagon-like peptide-1 (GLP-1) ± Basal insulin (loose and fixed combination) ± OADs
Patients will continue their antidiabetic treatment as per usual clinical practice at the discretion of their own treating physician
干预措施: Glucagon-like peptide-1 (GLP-1) (Drug)
结局指标
主要结局
Participant invited to consent and consented via e-signature (Yes/No)
时间窗: During Screening (Week -2 to week 0 )
Measured as count of participants.
Participant with at least 70% unblinded CGM (continuous glucose monitoring) data (Yes/No)
时间窗: From time of first unblinded CGM measurement until 10 weeks after the time of first unblinded CGM measurement
Measured as Count of participants.
Participant completion of questionnaires and per protocol planned remote visits (RVs)
时间窗: From week 0 until end of study (week 12)
% of questionnaires and RVs completed.
次要结局
- Time below range (TBR) L2 (below 3.0 mmol/L)(From time of first unblinded CGM measurement (week 2) until time of last unblinded CGM measurement (week 12))
- Coefficient of variation (CV) of glucose measurements(From time of first unblinded CGM measurement (week 2) until time of last unblinded CGM measurement (week 12))
- Time in range (TIR) (3.9-10 mmol/L)(From time of first unblinded CGM measurement (week 2) until time of last unblinded CGM measurement (week 12))
- Time above range (TAR) (above 10 mmol/L)(From time of first unblinded CGM measurement (week 2) until time of last unblinded CGM measurement (week 12))
- Time below range (TBR) L1 (3.0-3.9 mmol/L)(From time of first unblinded CGM measurement (week 2) until time of last unblinded CGM measurement (week 12))
- Mean glucose(From time of first unblinded CGM measurement (week 2) until time of last unblinded CGM measurement (week 12))
- Participant with at least 70% heart rate (pulse) data (Yes/No)(From time of first heart rate measurement (week 0) until 12 weeks after the time of first heart rate measurement)